Amphetamine Use Disorders
9
1
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
tTIS Targeted of the Striatum as an Intervention for MUD Patients
Closed-loop tACS Modulation for the Core Clinical Features of Drug Addiction
Individualized Neuromodulation for the Core Clinical Features of Drug Addiction
Effects of Repetitive Transcranial Magnetic Stimulations in Patients With Amphetamine Use Disorders
Closed-loop cTBS for the Core Clinical Features of Methamphetamine Use Disorder
Neurocognitive Empowerment for Addiction Treatment (NEAT) in Opioid Use Disorder and Amphetamine Use Disorder
Transcranial Magnetic Stimulation for Treatment of Methamphetamine Use Disorder
Transcranial Direct Current Stimulation to Modulate Top-Down Regulation for Drug Craving in Methamphetamine Use Disorder
Oxytocin HIV Meth Study